> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Study Analyzes Provider View of Boxed Warnings
- URL: https://www.fdaweb.com/fda-study-analyzes-provider-view-of-boxed-warnings/
- Published: 2024-09-03T12:00:00.000Z
- Updated: 2026-09-14T14:40:16.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5157699

A study conducted by CDER and outside researchers of healthcare provider (HCP) considerations of Boxed Warnings when making patient treatment decisions showed that they are only one of several factors that can influence providers’ treatment decisions. A study [description](https://www.fda.gov/drugs/spotlight-cder-science/prescriber-perceptions-boxed-warnings-qualitative-study?ref=fdaweb.com) says researchers held lengthy interviews with primary care physicians and specialists on treatment scenarios involving an oral antiviral medicine to treat hepatitis C and an estrogen vaginal insert to treat vulvovaginal atrophy.

“The labeling for each medicine contained a Boxed Warning, but the Boxed Warning for these medicines varied in text length and number of identified risks,” the post says. “The Boxed Warning in the hepatitis scenario was shorter and addressed only one risk, while the Boxed Warning in the vulvovaginal scenario was longer and addressed multiple risks.”

FDA says some HCPs found the Boxed Warnings more useful than others. “For instance,” it says, “HCPs who had more experience treating patients with the conditions were well aware of the risk information presented in the labeling and found the Boxed Warning to be less useful.”

HCP said the Boxed Warnings were one of several factors that influence their treatment decision-making and described prioritizing individual patient factors when making treatment decisions, including insurance coverage, patient socioeconomic status, and health status.

The report concludes that the research “provides novel insights into how Boxed Warnings fit within the context of HCP treatment decision-making and their communication with patients. These findings also underscore the nuanced complexity and context-specific nature of individual patient benefit-risk decisions.”